Human Epigenetic Reprogramming | Biological Systems Engineer

Marc Malone is a biomedical scientist and the founder of Airmid Biogenetics. He is the first known individual to document in vivo human epigenetic reprogramming, restoring multiple silenced genes & receptors on simultaneous chromosome loci, done without DNA editing or toxicity. His work integrates molecular biology, oncology, pharmacology, and systems-level biochemistry to develop therapeutic strategies that challenge conventional genetic medicine. His case is the only clinically verified human instance of multi-chromosomal gene restoration, with ESR1 (Estrogen) and PGR (Progesterone) genes reprogrammed and confirmed via third-party comparative biopsies, paving the way for a therapeutic modality across diseases including cancer, endocrinology & fertility, autoimmunity and neurology where these genes are often significant factors.

Following the terminal diagnosis of his wife with highly aggressive, refractory triple-negative breast cancer that failed all conventional treatments, Marc designed and implemented a compassionate-use treatment protocol that resulted in unprecedented clinical outcomes, including metastatic tumor regression, a tripled survival rate against all meta-analyses baselines, and gene restoration. Concurrent reduction in CTCs, KI-67, TP53, PMS2 and KMT2C mutational burden with the first human eradication of cancer stem cell (CSC) molecular pathways; Notch and the Hedgehog-GLI2 axis, was also documented, without toxicity. Setting the potential for a truly curative path in oncology due to reprogramming and expression modulation. The treatment was clinically reviewed by oncologists and formally MD peer-reviewed as a preprint. It also received informal review and feedback approval from dozens of MDs, and PhDs in genetics, pharmacology and biochemistry prior to submission.

His ongoing research focuses on cancer stem cell suppression, gene reactivation, and metabolic-genetic interface design for disease prevention and reversal. Driven by personal loss and the urgent need to treat his son's neurodevelopmental and terminal genetic condition. Marc’s work bridges compassionate innovation, novel methodology, and hard clinical data. He is committed to developing accessible, scalable therapeutic systems that may impact billions of lives worldwide.

ORCID ID

http://orcid.org/0009-0004-8968-9226

Reviewer Keywords